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OBJECTIVES The aim of this study was to investigate the relationships between future coronary heart
disease (CHD) events and baseline silent myocardial ischemia (SMI) and microalbuminuria
(MA) in subjects with type 2 diabetes (T2D) free from known CHD.
BACKGROUND Coronary heart disease is often asymptomatic in subjects with diabetes. There is limited
information on the prognostic value of SMI and MA in this group.
METHODS Eighty-six patients with T2D and no history of CHD were studied (43 with MA individually
matched with 43 normoalbuminuric patients; mean [SD] age 62 [7] years, 62 men).
Metabolic assessment, three timed overnight urine collections for albumin excretion rate, a
treadmill exercise test and ankle brachial index (ABI) were performed at baseline. Patients
were followed for 2.8 years.
RESULTS Forty-five (52%) patients had SMI during treadmill testing. At review, there had been 23
coronary (CHD) events in 15 patients. Univariate Cox regression analysis showed that CHD
events were significantly related to baseline ABI (p  0.014), SMI (p  0.020), MA (p 
0.046), 10-year Framingham CHD risk 30% (p  0.035) and fibrinogen (p  0.026). In
multivariate analysis, SMI was the strongest independent predictor of CHD events (p 
0.008); risk ratio (95% confidence interval) for SMI: 21 (2 to 204). In the prediction of CHD
events, SMI showed higher sensitivity and positive predictive value than MA or Framingham
calculated CHD risk.
CONCLUSIONS The presence of baseline SMI and MA are associated with future CHD events in
asymptomatic patients with T2D and may be of practical use in risk stratification. (J Am
Coll Cardiol 2002;40:56–61) © 2002 by the American College of Cardiology Foundation
Coronary heart disease (CHD) is the leading cause of death
in patients with type 2 diabetes (T2D), is often asymptom-
atic (1) and may present without warning as acute myocar-
dial infarction (AMI), heart failure, arrhythmia or sudden
death. In AMI (2) and heart failure (3), mortality is
increased in the presence of T2D, thus emphasizing the
potential value of identifying high-risk asymptomatic indi-
viduals with diabetes.
Microalbuminuria (MA) is present in approximately 25%
of patients with T2D (4) and is associated with a doubling
of the risk of early death, mainly from CHD (5). Mi-
croalbuminuria has been defined by consensus, based on risk
of renal disease, as a urinary albumin excretion rate between
20 and 200 g/min, though rates of 10.6 g/min have
been linked to increased macrovascular events in T2D (6).
Silent myocardial ischemia (SMI) can be detected by
various methods (7,8). Using treadmill exercise testing, SMI
has been defined as exercise-induced ST-segment depres-
sion in the absence of CHD symptoms (9), and, in men free
from known CHD, this finding has been associated with
increased mortality (10,11). There is very little data on the
prognostic value of SMI, detected by any method, in
asymptomatic patients with T2D (7,12–14).
We have previously shown that T2D is associated with a
high prevalence of SMI, especially in those with MA (15).
This cohort, free from symptoms of CHD at baseline, has
been followed to determine the influence of SMI and MA
on prognosis.
METHODS
Patient population. Baseline clinical characteristics and
methods have been described previously (15). Briefly, 86
patients with T2D and no history of cardiac disease were
studied: 43 with MA (albumin excretion rate [AER] 10.5
to 200 g/min) individually matched with 43 normoalbu-
minuric patients (AER  10.5 g/min) for age (2 years),
gender, diabetes duration (3 years) and smoking status
(never/previous/ex).
Methods. All patients performed three timed overnight
urine collections to assess AER and treadmill exercise
testing for SMI. Ankle brachial index (ABI), echocardiog-
raphy, ambulatory blood pressure (BP) monitoring, auto-
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nomic function testing and fasting blood testing for meta-
bolic parameters were performed. Exercise tests were
reported blind, and SMI was defined as 1 mm down
sloping or horizontal ST-segment depression from baseline
occurring 80 ms after the J point for three consecutive beats.
A test was defined as suboptimal if the patient failed to
achieve 85% of their age-predicted maximum heart rate.
Ten-year probability of coronary events (the Framingham
10-year CHD risk) were calculated using the software
package supplied with the Joint British Recommendations
on the Prevention of Coronary Heart Disease (16). For
technical reasons, accurate echocardiographic measurements
of the left ventricle were possible in only 67 subjects.
Follow-up data and definition of events. All patients
were under regular review at diabetes clinics and received
detailed structured hospital annual review. The following
information was recorded from the most recent annual
review proforma: diabetes treatment, medication, claudica-
tion, BP, body mass index (BMI), glycated hemoglobin
(HbA1c), lipids, creatinine, urinary albumin-creatinine ra-
tio, smoking status, alcohol intake and information regard-
ing CHD events. When a CHD event had occurred,
hospital casenotes were reviewed for verification and deter-
mination of the precise timing of the event. Predetermined
primary end points were as follows: 1) sudden cardiac death
was defined as sudden unexplained death; 2) AMI was
defined as chest pain with characteristic electrocardiogram
(ECG) or creatine kinase changes; and 3) new onset angina
was defined as exercise-related chest discomfort diagnosed
clinically or by investigation. If a patient experienced more
than one event during follow-up, then only the first was
recorded, and no additional data was used for survival
analysis. If two events occurred simultaneously, then the
more severe event was recorded.
Calculation of test performance. Patients were recruited
as matched pairs of microalbuminuric and normoalbumin-
uric patients. Events occurring within the shorter duration
of follow-up (median [SD] 2.5 [0.9] years) for individuals
within each pair were used to calculate sensitivity, specificity
and positive and negative predictive value.
Laboratory methods. Glycated hemoglobin, lipids and
fibrinogen were measured using standard assays. Urinary
albumin concentration was determined using radioimmu-
noassay (interassay coefficient of variation of 3.6% at a urine
concentration of 4.95 mg/l) (17).
Statistical analysis. Results are presented as means (SD) or
medians (range). Chi-squared or Fisher’s exact test were
used to compare categorical data. For continuous variables,
differences between groups were compared using either the
two sample Students t test or the Mann-Whitney U test.
Results were considered statistically significant if p  0.05
unless otherwise stated. Kaplan-Meier survival curves were
computed for categorical risk factors, and comparison of
survival curves was performed using the single variable
log-rank test. Univariate Cox regression analyses were
performed with coronary event as the outcome variable. The
following univariate predictors were tested: age, gender,
diabetes duration, smoking status, baseline claudication,
BMI, clinic and 24-h ambulatory BP, total cholesterol,
high-density lipoprotein cholesterol, HbA1c, fibrinogen,
AER, MA, positive exercise test, ABI, echocardiographi-
cally determined left ventricular mass index, number of
abnormal autonomic function tests, heart rate variability and
calculated Framingham coronary risk (incorporating ECG
evidence of left ventricular hypertrophy). Univariate predic-
tors with p  0.10 were entered into multivariate Cox
regression analysis. Calculations were performed using the
Minitab (Minitab Inc., State College, Pennsylvania) and
SPSS (SPSS Inc., Surrey, United Kingdom) statistical
packages. The study was approved by our local ethics
committee, and all patients gave informed consent.
RESULTS
Baseline clinical characteristics. Baseline characteristics
have been presented previously (15). Briefly, microalbumin-
uric patients were more likely to have symptoms of claudi-
cation, peripheral neuropathy and have evidence of diabetic
retinopathy compared with those with normoalbuminuria
(Table 1). Those with MA also had increased BMI,
increased clinic and ambulatory systolic BP, increased fi-
brinogen and HbA1c, reduced ABI and reduced heart rate
variability.
Treadmill exercise testing. Compared with normoalbu-
minuric patients, those with MA had a higher prevalence of
positive tests (28 vs. 17, p  0.05), exercised for shorter
periods (5.0 vs. 7.1 min, p  0.01), performed less work (6
vs. 8 METs, p  0.01), achieved lower heart rates, had
more suboptimal tests and a higher number of negative
suboptimal tests (15).
Medication at baseline and review. Patients with either
MA or SMI were more actively treated than patients
without. Those with MA were more likely to be prescribed
beta-blockers (number of patients: 8 vs. 1) at baseline and
more likely to be prescribed aspirin (28 vs. 13), angiotensin-
converting enzyme inhibitors (22 vs. 10), beta-blockers (14
vs. 3), nitrates (15 vs. 2) and statins (22 vs. 4) at final review.
Those with SMI were more likely to be prescribed aspirin
Abbreviations and Acronyms
ABI  ankle brachial index
AER  albumin excretion rate
AMI  acute myocardial infarction
BMI  body mass index
BP  blood pressure
CHD  coronary heart disease
ECG  electrocardiogram
HbA1c  glycated hemoglobin
MA  microalbuminuria
SMI  silent myocardial ischemia
T2D  type 2 diabetes
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(24 vs. 14), beta-blockers (15 vs. 2) and nitrates (16 vs. 1) at
final review.
CHD events. Follow-up data were obtained in all patients.
Median (range) follow-up was 2.8 (1.3 to 4.9) years during
which time patients were attending diabetes clinics and were
receiving standard clinical advice on appropriate risk factor
management. At the time of follow-up, there had been 23
CHD events (cardiac death, 3; AMI, 7; new-onset angina,
13) in 15 patients (annual patient event rate  15/[86 
2.8]  6.2%).
Relationship of SMI and MA to CHD events. Figures 1
and 2 show Kaplan-Meier CHD event-free survival plots
for patients with and without SMI and for patients with and
without MA. Comparing single risk factors, SMI was more
strongly related to the presence of CHD events than the
presence of MA (log-rank test: 8.7, p  0.003 vs. 4.8, p 
0.029). Figure 3 shows a comparison of coronary event-free
survival for the following subgroups: 1) patients with neither
SMI nor MA; 2) patients with MA but no SMI; 3) patients
with SMI but no MA; and 4) patients with both SMI and
MA (n  28). Patients with neither risk factor (n  26)
were less likely to experience CHD events compared with
the remaining patients (log-rank test 4.6, p  0.03).
Patients with both SMI and MA were much more likely to
experience CHD events compared with other patients
(log-rank test 11.3, p  0.0008).







Age (yrs) 62 (46–74) 62 (51–73) 62 (52–72)
Gender (M/F)* 62/24 31/12 31/12
Known diabetes duration (yrs) 7 (1–23) 7 (1–23) 7 (1–21)
Smoking status (present/ex/never)* 18/45/23 8/24/11 10/21/12
Albumin excretion rate (g/min) 10 (1–164) 28 (11–164) 4 (1–9)§
Diet/tablets/insulin* 14/53/19 10/23/10 4/30/9
BMI (kg/m2) 29.8 (5.0) 30.0 (4.8) 27.1 (4.8)†
Intermittent claudication* 10 8 2†
Ankle brachial index 1.08 (0.22) 1.06 (0.27) 1.14 (0.27)†
Peripheral neuropathy symptoms 23 16 7†
Retinopathy* 27 17 10
Clinic systolic BP (mm Hg) 156 (23) 161 (25) 150 (20)†
Clinic diastolic BP (mm Hg) 84 (10) 85 (10) 83 (10)
24-h systolic BP (mm Hg) 136 (12) 140 (13) 132 (11)‡
24-h diastolic BP (mm Hg) 78 (7) 79 (7) 77 (7)
Abnormal autonomic function tests 1 (0–5) 1 (0–5) 1 (0–4)
SDNN 122 (37) 115 (33) 131 (40)†
LVH on ECG* 9 3 6
LVMI (g/m2.7) 56 (33–89) 62 (34–87) 52 (33–89)†
Creatinine (mol/l) 90 (63–152) 89 (63–152) 90 (67–146)
Fasting plasma glucose (mmol/l) 10.0 (3.8) 10.6 (3.9) 9.4 (3.6)
HbA1c (%) 8.3 (1.5) 8.7 (1.6) 7.9 (1.3)†
Total cholesterol (mmol/l) 5.6 (1.0) 5.6 (1.0) 5.5 (1.1)
HDL cholesterol (mmol/l) 1.1 (0.3) 1.0 (0.3) 1.2 (0.4)
Triglyceride (mmol/l) 1.6 (0.5–8.3) 1.8 (0.7–6.3) 1.3 (0.5–8.3)
Fibrinogen (g/l) 3.9 (2.5–8.0) 4.1 (2.8–7.3) 3.6 (2.5–8.0)‡
*Number; †p  0.05; ‡p  0.01; §p  0.001 (comparing MA and NA groups). Data are mean (SD) or median (range) unless stated.
BP  blood pressure; BMI  body mass index; HbA1c  glycated hemoglobin; HDL  high-density lipoprotein; LVH on ECG  left ventricular hypertrophy on
electrocardiograph; LVMI  left ventricular mass index; MA  microalbuminuric; NA  normoalbuminuric; SDNN  SD of normal RR intervals.
Figure 1. Coronary event-free survival in asymptomatic patients with type
2 diabetes with (dotted line) and without (solid line) silent myocardial
ischemia. p  0.003 (log-rank test).
Figure 2. Coronary event-free survival in asymptomatic patients with type
2 diabetes with (dotted line) and without (solid line) microalbuminuria.
p  0.03 (log-rank test).
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Cox regression: predictors of CHD events. When con-
sidered as a continuous variable, baseline ABI was the
variable most strongly related to the presence of future
CHD events (Table 2). However, when considered as a
discrete variable (ABI or 0.9) (18), the relationship was
not significant (p  0.08). The presence of SMI, MA and
Framingham 10-year CHD risk30% were all significantly
related to future CHD events. When considered as a
continuous variable, baseline fibrinogen was also linked to
future CHD events. In multivariate analysis, the only
independent predictors of CHD events were SMI (p 
0.008) and ABI (p  0.032). Microalbuminuria was not
independently related to CHD events after correcting for
the effects of SMI, ABI, BMI and fibrinogen. Hazard ratios
(95% confidence interval) for SMI were 21 (2 to 204) and
for ABI were 17 (1.3 to 213) for a difference in ABI of one
unit. When both MA and SMI were entered together as
predictor variables in a multivariate Cox regression model,
only SMI (beta [se], 2.2 [1.0]; p  0.03) was independently
related to CHD events (beta [se], 1.2 [0.8]; p  0.11 for
MA).
Individual and combined test performance. Silent myo-
cardial ischemia was the single most sensitive test for the
identification of patients developing CHD events (Table 3).
Ankle brachial index showed low sensitivity (50%) for
predicting coronary events when considered as a discrete
variable (threshold  0.9). When different ABI threshold
values were used, improved sensitivity occurred at the
expense of reduced specificity and positive predictive value.
Combining SMI and MA results identified patient groups
at particularly high and low risk of future CHD events.
DISCUSSION
This study has shown that the presence of SMI, as assessed
by exercise ECG, is strongly and independently related to
subsequent CHD events in asymptomatic patients with
T2D.
Prevalence of SMI and CHD events. The high preva-
lence of SMI and the high event rate in this study is
probably explained by the selection of only T2D patients,
the age of the patients, the high proportion (50%) with MA
and the geographical location of the study population
(northeast England) where there is a high background
prevalence and incidence of CHD (19).
SMI and prognosis. To our knowledge there has been
only one previous study showing that ST-segment change
during treadmill exercise testing has prognostic value in
asymptomatic patients with T2D (12). However, this study
was limited by male selection, poor characterization of
diabetes type, incomplete follow-up, wide variation of
follow-up duration and failure to assess albuminuria status.
Two recent studies of the relationship between ST-segment
change during exercise and coronary events have yielded
negative results (7,13). The relatively young age of some
patients studied, the grouping of subjects with type 1 and
type 2 diabetes and incomplete follow-up may have influ-
enced the results of these studies. In the study presented
here, angina was the first manifestation of CHD in about
half of the subjects, the others presenting with AMI or
cardiac death. Thus, the presence of SMI is not simply a
prelude to symptomatic (loud) ischemia (20). Similar find-
ings were noted in the Framingham study and other studies
(21), and the proportions of patients presenting with hard
events were also similar in population-based studies of
asymptomatic subjects with SMI (22,23).
SMI and test performance. Rubler et al. (12) found that
ST-segment change during treadmill exercise testing in
diabetes had a low sensitivity (50%) and high specificity
(83%) in the prediction of CHD events. The higher
sensitivity of treadmill exercise testing in our study is
probably explained by patient selection. Our patients were
Table 2. Cox Regression: Univariate Predictors of CHD Events
Event No Event p Value
Number of patients 15 71
Ankle brachial index 0.98 (0.42–1.23) 1.12 (0.52–1.55) 0.014
Silent myocardial ischemia 14 (93) 31 (44) 0.020
Microalbuminuria 13 (87) 30 (42) 0.046
Framingham 10-year CHD risk 30% 8 (53) 23 (27) 0.035
Fibrinogen (g/l) 4.5 (3.4–7.8) 3.8 (2.5–8.0) 0.026
Data are number of patients, number of patients (proportion [%] of group) or for continuous variables: median (range).
Framingham 10-year CHD risk  30%  Framingham calculated 10-year coronary heart disease risk 30% (categorical).
Figure 3. Coronary event-free survival in asymptomatic patients with type
2 diabetes in the following subgroups: 1) neither silent myocardial ischemia
(SMI) nor microalbuminuria (MA); 2) SMI but not MA; 3) MA but not
SMI; and 4) both SMI and MA. p  0.03, comparing group 1 with
remaining patients; p  0.0008, comparing group 4 with remaining
patients.
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older (62 vs. 53 years) and a high proportion had MA.
These factors are likely to have increased the proportion of
patients with more severe CHD, which would increase the
sensitivity of treadmill testing. The high incidence of CHD
events in our study population would have increased the
positive predictive value compared with testing in lower risk
groups.
Influence of medication. Data on prescribed medication
and the risk factor changes during follow-up (data available
on request) strongly suggest that high event rates in patients
with SMI and MA have not been due to differences in
management.
MA and ABI as risk factors. To our knowledge, this is the
first study to show that ABI is significantly related to CHD
events in asymptomatic patients with T2D. However, the
data suggests that use of threshold ABI values lack the high
sensitivity and specificity required for clinical use. Studies in
the general population have shown the prognostic value of
ABI (24), and further studies in diabetes are needed to
determine if the test can be useful clinically. We have
confirmed the results of previous studies in patients with
T2D showing that the presence of MA is a significant
coronary risk factor (5,14).
Influence of exercise capacity. Inclusion in the present
study required patients to be ambulant and free from severe
chronic disease. However, 45% of the study patients exer-
cised for 6 min, and 13% had suboptimal tests. Although
exercise duration was less in patients experiencing a coro-
nary event (4.9 [3.4 to 10.0] vs. 6.3 [1.3 to 13.1] min), it was
not significantly related to CHD events in Cox regression
analysis. Vanzetto et al. (14) recently studied high-risk
subjects with T2D, a third of whom had evidence of
baseline CHD. In patients predicted by questionnaire to be
unable to perform treadmill exercise testing, large perfusion
defects on dipyridamole thallium-201 single-photon emis-
sion computed tomography predicted CHD events. Patients
predicted to be able to exercise were a lower risk group, and, in
these patients, treadmill testing was of no prognostic value. It
seems likely that exclusion of higher-risk subjects from tread-
mill testing in the Vanzetto et al. (14) study reduced the power
to show the prognostic value of SMI.
Study limitations. The sample size and number of cardio-
vascular events in this study are relatively small, and confi-
dence intervals around estimates of test performance are
likely to be wide. Patients in the study were of European
race and were selected from a geographical area with a high
background prevalence of CHD. Event rates in this popu-
lation were higher than in many previous studies, and results
may not be applicable in lower-risk populations. Data on
prognosis and SMI refer to exercise-induced ST depression;
other detection modes were not assessed.
Conclusions. This study has shown that baseline SMI and
MA are significantly related to future CHD events in
asymptomatic patients with T2D. The relationship of SMI
to CHD events is independent of the presence of MA. This
study suggests that SMI, MA and ABI could be of practical
value in risk stratification.
Further studies are required to clarify the natural history
of CHD in optimally managed medically treated asymp-
tomatic patients with diabetes and, in particular, to accu-
rately quantify the risk of hard and soft CHD events,
arrhythmic death and heart failure. Future studies should
aim to determine appropriate risk thresholds for initiation of
anti-ischemia therapy and for CHD screening to identify
those who are likely to benefit from revascularization.
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Table 3. Comparison of Individual and Combined Test Performance in the Prediction of
Coronary Events
No. of
Patients Sensitivity Specificity PPV NPV
Individual
ABI  0.90 13 50 88 31 94
SMI 45 100 53 20 100
MA 43 78 53 16 95
Framingham CHD risk 30% 31 67 68 19 95
Fibrinogen  4.4 g/l 21 50 78 19 94
Combined
Both SMI and MA 28 78 73 25 97
Neither SMI nor MA 26 0 66 0 85
Either (SMI or MA) or both 60 100 34 15 100
Data are % unless stated. Mean (SD) follow-up length is 2.5 (0.9) years. Percentage of patients experiencing CHD event per
year: (100*9)/(86*2.5)  4.2%.
ABI  ankle brachial index; Framingham CHD risk 30%  Framingham calculated 10-year coronary heart disease risk
(categorical); MA  microalbuminuria; NPV  negative predictive value; PPV  positive predictive value; SMI  silent
myocardial ischemia.
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